Navigation Links
Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial
Date:10/4/2007

s / Nestle Pre-Clinical Studies

The final results of the two pre-clinical dose response trials announced to the market on December 14th, 2006, confirmed that when given orally, Phospha E(R) significantly reduced many of the key biomarkers associated with metabolic syndrome, inflammation and cardiovascular disease. Additionally, the most appropriate dosage required to commence human clinical trials was also determined. In these trials, animals treated with varying doses of Phospha E were shown to have statistically significant reductions in key parameters such as plaque formation, aortic vascular dysfunction, cholesterol, triglycerides and LDL-C (so called bad cholesterol).

About Metabolic Syndrome

Metabolic syndrome is characterized by a group of metabolic risk factors - abdominal obesity and elevated blood pressure, cholesterol, triglycerides and blood glucose. The root causes of metabolic syndrome are overweight/obesity, physical inactivity, and genetic factors. It is estimated that about 27% of adults in the US have metabolic syndrome and that one in three overweight or obese people in the US have this condition. The condition is being diagnosed with increasing frequency.

About Phospha E(R)

Phospha E(R) is a patented derivative of vitamin E that has superior properties compared to its parent molecule. For example, Phospha E has been shown to be better absorbed than vitamin E, both orally and through the skin, to lower cholesterol and triglycerides, prevent the formation of plaque in heart arteries, as well as having unique anti-inflammatory properties. Phospha E has applications across all three nutraceutical market segments, and is currently sold internationally as a dietary supplement by NBTY Inc. (under the name of Ester-E(TM)) and is marketed worldwide in the personal care market as Vital ET(TM) by ISP Corporation.

Safe Harbor Statement

This press release contains forward-looking statements based on current expectatio
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
5. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
6. AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , and DURHAM, N.C. , July ... today announced its acquisition of assets related to the ... PFE ) that had previously been obtained as part ... also acquired all of Pfizer,s rights to the "Icagen" ... brand and will provide comprehensive services for ion channel ...
(Date:7/2/2015)... TOKYO , July 2, 2015  Konica Minolta, ... today announced that it has acquired Sawae Technologica Ltda., ... Brazil , through its Brazilian healthcare ... . Local Brazil ... increasing population exceeding 200 million, significant healthcare ...
(Date:7/2/2015)... 2, 2015  The Commission for Certification in ... an organization that represents pharmacists in acute and ... continuing education for recertification of Certified Geriatric Pharmacists.  ... programs for this purpose.  ASHP will join the ... for the CCGP Professional Development Program. ...
Breaking Medicine Technology:Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3Commission for Certification in Geriatric Pharmacy Adds ASHP as Professional Development Program Provider 2
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that ... Food and Drug Administration for its Abbreviated New ... Powder for Solution. Perrigo is expecting to begin ... under store brand labels and is comparable to ...
... BATESVILLE, Ind., Oct. 6 Hill-Rom Holdings, Inc. (NYSE: ... has unanimously approved enhancements to the Company,s corporate ... of majority voting in uncontested elections. The ... for a majority voting standard for the election of directors ...
Cached Medicine Technology:Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350 2Hill-Rom Announces Corporate Governance Enhancements 2Hill-Rom Announces Corporate Governance Enhancements 3Hill-Rom Announces Corporate Governance Enhancements 4
(Date:7/2/2015)... ... July 02, 2015 , ... The American ... introduction of the Stop Overdose Stat (S.O.S.) Act of 2015 on June 23, ... this Act seeks to decrease drug overdose – especially of heroin and opioid ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... In 2012, Patrick Achebe realized that the ... was alone. He sat down to write his first poem, and three years later he ... that was special and worth sharing with the world. "I have always believed that the ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Global leader and ... in compression socks designed for men. , For style that’s quick on its ... daily routine. This is great news for men everywhere because a simple change in ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... Healthcare Delivery Coalition met for the late June Web-based session, the speakers discussed ... reimbursement schemes and managing high-risk patients through coordinated care. , During the session, ...
(Date:7/2/2015)... ... 02, 2015 , ... Facial plastic surgery is about more ... an art and science that goes into successful facial reconstruction and contouring. Dr. ... and lives of more than 2,500 satisfied facelift and neck lift patients alone. ...
Breaking Medicine News(10 mins):Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 4Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3
... of aggressive prostate cancer is an elevated rate of increase ... study. The study found that a pre-treatment rate of ... was strongly associated with a high risk of death from ... factor than any other single high-risk indicator, such as a ...
... AMO Complete Moisture Plus Multi-Purpose Solution. For an ongoing government ... to an increased risk of Acanthamoeba keratitis, a rare ... cause permanent vision loss or blindness. The Centres for Disease ... of the disease occur in contact lens users. ...
... (AMSA) National President, Mr Rob Mitchell, today said expensive ... undergraduate admission testing for entry into medical school. ... students are paying as much as $1,700 to attend ... scoring well on the Undergraduate Medical Admission Test (UMAT). ...
... looking for a mate run great risks. Scientists from ... Research Institute in Panama present a new take on ... Public Library of Science. The researchers report that females ... their predators as they sequentially visit and assess potential ...
... fire ants (RIFAs), which have caused trouble in Florida ... Colonies of the tiny, highly aggressive insects have been ... recent years, have caught the attention of Virginia Tech ... increasing number of fire ant infestations. ,"Virginia ...
... neurocognitive functioning, including decision-making capabilities. ... drinking, common among college students, is associated with ... neurocognitive effects of binge drinking during young adulthood ... tend to have poorer neurocognitive functioning, including decision ...
Cached Medicine News:Health News:High Pretreatment PSA Velocity Predicts Worse Outcome 2Health News:Contact Lens Wearers Warned Against Using AMO Solution 2Health News:Contact Lens Wearers Warned Against Using AMO Solution 3Health News:Scientists Report New Take on Sexual Signaling 2Health News:Fire Ants are Emerging Nuisance for Virginians 2Health News:Fire Ants are Emerging Nuisance for Virginians 3Health News:Binge Drinking Leads to Neurocognitive Deficits Among College Students 2Health News:Binge Drinking Leads to Neurocognitive Deficits Among College Students 3
... Streck-Kleen is an enzymatic cleanser for ... Coulter® Counters. The 475ml bottle has a ... MD Series instruments that require manual addition ... is a feature of this product. The ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
... balanced electrolyte solution manufactured for use as ... sizing. Streck-Diluent III is for use on ... JS, JT, S-Plus IV, V, VI with ... 1400 and 1600. The shelf life is ...
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
Medicine Products: